# US 2001/0024651 A1 · Method for inducing a systemic immune response to an antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024651 A1
- Document ID: US20010024651A1
- Status: Published application
- Kind: A1
- Application number: 09/817,649
- Filed: 2001-03-26
- Published: 2001-09-27
- Earliest claimed: 1996-03-22
- Inventors: Jackie R. See; Darryl M. See
- Web page: https://patentgrep.com/patent/US20010024651A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 39/12: Viral antigens
- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method is provided for inducing a systemic immune response to an antigen selected from inactivated HIV I and HIV II antigens in a mammal. The method comprises orally administering lyophilized multilaminar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

## Claims

### Claim 1

A method for stimulating a systemic immune response to an antigen selected from the group consisting of inactivated HIV I and HIV II antigens and combinations thereof in a mammal comprising:
incorporating the antigen into liposomes having a size of from about 20 nm to about 20 microns;
lyophilizing the antigen-containing liposomes; and
orally administering an effective amount of the antigen containing liposomes to a mammal, whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a systemic immune response.

### Claim 2 (depends on 1)

A method as claimed in claim 1 wherein the liposomes have a size of from about 200 nm to about 10 microns.

### Claim 3 (depends on 1)

A method as claimed in claim 1, wherein the liposomes have a size of from about 1 to about 5 microns.

### Claim 4 (depends on 1)

A method as claimed in claim 1, wherein the liposomes are multi-lamellar.

### Claim 5 (depends on 1)

A method as claimed in claim 1, wherein the lyophilized liposomes are coated with an enteric coating.

### Claim 6 (depends on 1)

A method as claimed in claim 1, wherein the antigen is an attenuated or killed microorganism.

### Claim 7 (depends on 1)

A method as claimed in claim 1 wherein the liposomes comprise large liposomes.

### Claim 8 (depends on 1)

A method as claimed in claim 1 wherein the liposomes comprise small, medium and large liposomes.

### Claim 9 (depends on 1)

A method as claimed in claim 1 wherein the liposomes comprise at least 5% by volume small liposomes, at least 10% by volume medium liposomes and at least 20% by volume large liposomes.

### Claim 10 (depends on 1)

A method as claimed in claim 1 wherein the liposomes comprise about 10% by volume small liposomes, about 25% by volume medium liposomes and about 65% by volume large liposomes.

### Claim 11 (depends on 1)

A method as claimed in claim 1 wherein the liposomes comprise at least two different antigens.

### Claim 12

A preparation for oral administration to a mammal capable of stimulating a systemic immune response to at least one antigen selected from the group consisting of inactivated HIV I and HIV II antigens, said preparation comprising an effective amount of lyophilized liposomes, said liposomes containing the at least one antigen having a size, before lyophilization, of from about 200 nm to about 20 microns.

### Claim 13 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes have an average size of from about 200 nm to about 10 microns.

### Claim 14 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes have an average size of from about 1 micron to about 5 microns.

### Claim 15 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes are multi-lamellar.

### Claim 16 (depends on 12)

A preparation as claimed in claim 12 further comprises an enteric coating.

### Claim 17 (depends on 12)

A preparation as claimed in claim 12 in the form of a pill.

### Claim 18 (depends on 12)

A preparation as claimed in claim 12 in the form of a capsule.

### Claim 19 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise small liposomes.

### Claim 20 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise medium liposomes.

### Claim 21 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise large liposomes.

### Claim 22 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise small, medium and large liposomes.

### Claim 23 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise at least 5% by volume small liposomes, at least 10% by volume medium liposomes and at least 20% by volume large liposomes.

### Claim 24 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise about 10% by volume small liposomes, about 25% by volume medium liposomes and about 65% by volume large liposomes.

### Claim 25 (depends on 12)

A preparation as claimed in claim 12 wherein the liposomes comprise at least two different antigens.

### Claim 26

A method for stimulating a long term systemic immune response to at least one antigen selected from the group consisting of inactivated HIV I and HIV II antigens in a mammal comprising:
incorporating at least one antigen selected from the group consisting of inactivated HIV I and HIV II antigens into liposomes having at least two sizes within the range of from about 20 nm to about 20 microns;
lyophilizing the antigen-containing liposomes; and
orally administering an effective amount of the antigen containing liposomes to a mammal,
whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a long term systemic immune response to the at least one antigen.

### Claim 27 (depends on 26)

A method as claimed in claim 26 wherein the liposomes comprise small, medium and large liposomes.

### Claim 28 (depends on 26)

A method as claimed in claim 26 wherein the liposomes comprise at least 5% by volume small liposomes, at least 10% by volume medium liposomes and at least 20% by volume large liposomes.

### Claim 29 (depends on 26)

A method as claimed in claim 26 wherein the liposomes comprise about 10% by volume small liposomes, about 25% by volume medium liposomes and about 65% by volume large liposomes.

### Claim 30 (depends on 26)

A method as claimed in claim 26 wherein the liposomes comprise at least two different antigens.

### Claim 31

A preparation for oral administration to a mammal capable of stimulating a long term systemic immune response to at least one antigen selected from inactivated HIV I and HIV II antigens, said preparation comprising an effective amount of lyophilized liposomes, said antigen containing liposomes having at least two sizes before lyophilization ranging from about 200 nm to about 20 microns.

### Claim 32 (depends on 31)

A preparation as claimed in claim 31 wherein the liposomes comprise small, medium and large liposomes.

### Claim 33 (depends on 31)

A preparation as claimed in claim 31 wherein the liposomes comprise at least 5% by volume small liposomes, at least 10% by volume medium liposomes and at least 20% by volume large liposomes.

### Claim 34 (depends on 31)

A preparation as claimed in claim 31 wherein the liposomes comprise about 10% by volume small liposomes, about 25% by volume medium liposomes and about 65% by volume large liposomes.

### Claim 35 (depends on 31)

A preparation as claimed in claim 31 wherein the liposomes comprise at least two different antigens.

### Claim 36

A method for stimulating a systemic immune response to an antigen selected from the group consisting of inactivated HIV I and HIV II antigens and combinations thereof in a mammal comprising orally administering to a mammal an effective amount of the antigen incorporated into lyophilized liposomes having a size of from about 20 nm to about 20 microns whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a systemic immune response.

### Claim 37 (depends on 36)

A method as claimed in claim 36 wherein the liposomes have a size of from about 200 nm to about 10 microns.

### Claim 38 (depends on 36)

A method as claimed in claim 36, wherein the liposomes have a size of from about 1 to about 5 microns.

### Claim 39 (depends on 36)

A method as claimed in claim 36, wherein the liposomes are multi-lamellar.

### Claim 40 (depends on 36)

A method as claimed in claim 36, wherein the lyophilized liposomes are coated with an enteric coating.

### Claim 41 (depends on 36)

A method as claimed in claim 36, wherein the antigen is an attenuated or killed microorganism.

### Claim 42 (depends on 36)

A method as claimed in claim 36 wherein the liposomes comprise large liposomes.

### Claim 43 (depends on 36)

A method as claimed in claim 36 wherein the liposomes comprise small, medium and large liposomes.

### Claim 44 (depends on 36)

A method as claimed in claim 36 wherein the liposomes comprise at least 5% by volume small liposomes, at least 10% by volume medium liposomes and at least 20% by volume large liposomes.

### Claim 45 (depends on 36)

A method as claimed in claim 36 wherein the liposomes comprise about 10% by volume small liposomes, about 25% by volume medium liposomes and about 65% by volume large liposomes.

### Claim 46 (depends on 36)

A method as claimed in claim 36 wherein the liposomes comprise at least two different antigens.

### Claim 47 (depends on 1)

A method according to claim 1 wherein a the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without the presence of an adjuvant.

### Claim 48 (depends on 1)

A method according to claim 1 wherein the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without generating a typical adjuvant effect.

### Claim 49 (depends on 26)

A method according to claim 26 wherein the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without the presence of an adjuvant.

### Claim 50 (depends on 26)

A method according to claim 26 wherein the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without generating a typical adjuvant effect.

### Claim 51 (depends on 36)

A method according to claim 36 wherein the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without the presence of an adjuvant.

### Claim 52 (depends on 36)

A method according to claim 36 wherein the antigen containing liposomes are capable of being absorbed in the Peyer's patches of the gut of the mammal and are capable of being taken up by macrophages in the Peyer's patches to stimulate a systemic immune response without generating a typical adjuvant effect.
